Sotagliflozin Crystalline Forms Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing crystalline forms of sotagliflozin, particularly Form 1 and Form 2, face challenges with stability, especially under high water activity, and exhibit poor mechanical stability, wide particle size distribution, and uneven particle morphology, which complicates drug development and formulation processes.
Innovation Solution
Development of novel crystalline forms, including Form I, Form II, Form III, and Form VI, characterized by specific X-ray powder diffraction patterns and preparation methods, which offer improved stability, uniform particle size distribution, and enhanced solubility, facilitating better drug properties and industrial scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If existing crystalline Form 2 is used, then ease of manufacture is improved, but stability under high water activity deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying the crystallization conditions (solvent system, temperature, pH) to transform existing crystalline Form 2 into novel crystalline forms I, II, III, and VI. These new forms have different crystal lattice parameters and molecular packing arrangements that confer superior stability under high water activity while maintaining manufacturability through optimized preparation protocols.
Solution Approach 2:
The patent utilizes phase transitions by inducing controlled polymorphic transformations from existing crystalline Form 2 to novel crystalline forms. Through controlled changes in solvent composition, temperature, and crystallization kinetics, the patent achieves phase transitions that produce more stable crystal structures resistant to hydration and degradation under high water activity conditions.
2Ease of manufacture
If existing crystalline Form 2 is used, then ease of manufacture is improved, but mechanical stability deteriorates
Solution Approach 1:
The patent modifies crystallization parameters including solvent type, temperature profile, and addition rate to produce novel crystalline forms with enhanced mechanical stability. The controlled crystallization process generates crystals with improved internal stress distribution and defect structure, resulting in better mechanical strength and reduced crystal transformation during formulation processing.
3Ease of manufacture
If existing crystalline Form 2 is used, then ease of manufacture is improved, but particle size distribution deteriorates
Solution Approach 1:
The patent applies preliminary action by implementing pre-nucleation steps and controlled seed crystal addition before main crystallization. This preliminary preparation of nucleation sites and controlled growth conditions ensures uniform crystal nucleation and consistent particle size distribution from the outset, preventing the wide and uneven distribution observed in existing crystalline Form 2.
Solution Approach 2:
The patent utilizes periodic action through staged crystallization processes with controlled temperature cycling and incremental solvent addition. This periodic control of crystallization conditions promotes uniform crystal growth rates and maintains consistent particle size distribution throughout the manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystalline forms demonstrate enhanced stability, improved solubility, and uniform particle morphology, addressing the limitations of existing forms and making them more suitable for drug production and storage, with Form I and Form VI showing superior mechanical stability and Form II and Form III exhibiting higher solubility compared to existing Form 2.
Implementation Method 1
crystalline Form I can be prepared by dissolving a solid of sotagliflozin into an alcohol, ketone or cyclic ether to obtain a sotagliflozin solution, slowly adding water dropwise into the solution or adding the solution dropwise into water to obtain a solid precipitation
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.